<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02042027</url>
  </required_header>
  <id_info>
    <org_study_id>AMB70983</org_study_id>
    <nct_id>NCT02042027</nct_id>
  </id_info>
  <brief_title>Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions</brief_title>
  <official_title>Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the investigational drug Gamunex-C on the growth of blood
      vessels over the cornea. This study is being conducted by Dr. Balamurali Ambati at the Moran
      Eye Center at the University of Utah.

      The cornea is the clear outer front part of the eye. In corneal neovascularization, blood
      vessels grow over the cornea. Corneal neovascularization and ocular anterior segment
      inflammations are sight-threatening conditions. Lipid deposition and edema with subsequent
      scar formation can compromise corneal clarity irreversibly. Corneal neovascularization is
      also a well recognized risk factor for corneal graft failure. In its natural state, the
      cornea is a site of immune privilege well suited to tissue transplantation. Once
      vascularized, there is direct exposure of corneal antigens to circulating host immune
      mechanisms greatly increasing the chance of rejection [Collaborative Corneal Transplantation
      Study].

      Melting or inflammation in the anterior chamber, cornea, or ocular surface can cause
      irreversible scarring or destruction of the optical elements of the eye, which can compromise
      vision.

      Current standard of care for such conditions includes use of topical steroids and sometimes
      immunosuppressants (e.g., cyclosporine). These do not address a common underlying corneal
      neovascularization or melting.

      This is a Phase 1 clinical trial of subconjunctival IVIg (Gamunex-C) injection for treatment
      of corneal neovascularization in the setting of corneal transplantation with
      neovascularization. Candidates for corneal transplantation with corneal neovascularization in
      one or more quadrants crossing more than 0.5mm over the limbus will be identified for
      inclusion in our study.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to regress neovascularization</measure>
    <time_frame>at time of transplant</time_frame>
    <description>Ability of subconjunctival IVIg (Gamunex-C) injection to regress neovascularization and promote graft survival after corneal transplantation, or retard corneal/anterior segment inflammation in patients with progressive/refractory conditions (corneal melts, ocular cicatricial pemphigoid, or refractory anterior uveitis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability to regress neovascularization and promote graft survival</measure>
    <time_frame>28 weeks after transplant</time_frame>
    <description>ability of subconjunctival IVIg (Gamunex-C) injection to regress neovascularization and promote graft survival after corneal transplantation, or retard corneal/anterior segment inflammation in patients with progressive/refractory conditions (corneal melts, ocular cicatricial pemphigoid, or refractory anterior uveitis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to regress neovascularization and promote graft survival</measure>
    <time_frame>52 weeks after transplant</time_frame>
    <description>ability of subconjunctival IVIg (Gamunex-C) injection to regress neovascularization and promote graft survival after corneal transplantation, or retard corneal/anterior segment inflammation in patients with progressive/refractory conditions (corneal melts, ocular cicatricial pemphigoid, or refractory anterior uveitis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for immunosuppression</measure>
    <time_frame>week 28</time_frame>
    <description>need for immunosuppression at weeks 28 in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for immunosuppression</measure>
    <time_frame>week 52</time_frame>
    <description>need for immunosuppression at week 52 in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on corneal infections</measure>
    <time_frame>week 28</time_frame>
    <description>Effect on corneal infections or other side effects through week 28 in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on corneal infections</measure>
    <time_frame>Week 52</time_frame>
    <description>effect on corneal infections or other side effects through week 52 in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual outcome at week 28</measure>
    <time_frame>Week 28</time_frame>
    <description>visual outcome (by ETDRS chart) at week 28 in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual outcome at week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>visual outcome (by ETDRS chart) at week 52 in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of injections through week 28</measure>
    <time_frame>week 28</time_frame>
    <description>mean number of injections performed per patient through weeks 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of injections through week 52</measure>
    <time_frame>week 52</time_frame>
    <description>mean number of injections performed per patient through week 52 in patients receiving subconjunctival IVIg (Gamunex-C) injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue treatment in standard of care group</measure>
    <time_frame>Week 28</time_frame>
    <description>need for rescue treatment in the standard of care group through week 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue treatment in standard of care group</measure>
    <time_frame>week 52</time_frame>
    <description>need for rescue treatment in the standard of care group through week 52</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Corneal Neovascularization</condition>
  <condition>Corneal Graft Failure</condition>
  <condition>Anterior Segment Inflammation</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gamunex-C 50 mg subconjunctival injections, in addition to standard of care treatment (steroids and cyclosporine). One dose of Gamunex-C injection delivered four weeks prior to corneal transplant surgery and one dose at the time of corneal transplantation. Dose to be repeated if recurrence of corneal neovascularization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gamunex-C 50 mg subconjunctival injections, one dose injected for patients with active disease from corneal melts (peripheral ulcerative keratitis; Mooren's ulcer), ocular cicatricial pemphigoid, or anterior uveitis refractory to conventional therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gamunex-C</intervention_name>
    <description>Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>IVIg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Candidates for corneal transplantation (only one eye per patient would be enrolled)

          2. Patients with corneal neovascularization in one or more quadrants crossing more than
             1.0 mm over the limbus at time of enrollment in the study

          3. Patients with refractory anterior uveitis, non-responding corneal melts, or
             non-responding ocular cicatricial pemphigoid

          4. Willing and able to comply with clinic visits and study-related procedures

          5. Provide signed informed consent

          6. Age 18 or over

        Exclusion Criteria:

          1. Patients receiving antiangiogenic anti-VEGF medication either systemically or
             intravitreally for other pathology or who have received these drugs within 3 months of
             study enrollment

          2. Patients with active corneal infection requiring additional treatment modalities

          3. Patients receiving coumadin with INR &gt;2.0, other anti-thrombotic agents (e.g.,
             aspirin, Plavix) permitted at discretion of investigator

          4. History of CVA or MI within 6 months prior to study enrollment

          5. Uncontrolled BP- defined as SBP&gt;160 mmHg or DBP &gt;95mmHg while patient is sitting

          6. Pregnant or breast-feeding women

          7. Sexually active men* or women of childbearing potential** who are unwilling to
             practice adequate contraception during the study (adequate contraceptive measures
             include stable use of oral contraceptives or other prescription pharmaceutical
             contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device
             [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or
             jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not
             required for men with documented vasectomy. **Postmenopausal women must be amenorrheic
             for at least 12 months in order not to be considered of child bearing potential.
             Pregnancy testing and contraception are not required for women with documented
             hysterectomy or tubal ligation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Balamurali K Ambati, M.D., Ph.D., M.B.A.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John A. Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012 Sep;57(5):415-29. doi: 10.1016/j.survophthal.2012.01.007. Review.</citation>
    <PMID>22898649</PMID>
  </reference>
  <reference>
    <citation>Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001 Aug;12(4):242-9. Review.</citation>
    <PMID>11507336</PMID>
  </reference>
  <reference>
    <citation>Cho YK, Uehara H, Young JR, Tyagi P, Kompella UB, Zhang X, Luo L, Singh N, Archer B, Ambati BK. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci. 2012 Apr 30;53(4):2328-36. doi: 10.1167/iovs.11-8393.</citation>
    <PMID>22427553</PMID>
  </reference>
  <reference>
    <citation>Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009 May;16(5):645-59. doi: 10.1038/gt.2008.185. Epub 2009 Feb 5.</citation>
    <PMID>19194480</PMID>
  </reference>
  <reference>
    <citation>Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, Amin S, Kompella UB, Ambati BK. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci. 2007 May;48(5):2030-6.</citation>
    <PMID>17460257</PMID>
  </reference>
  <reference>
    <citation>Luo L, Zhang X, Hirano Y, Tyagi P, Barab√°s P, Uehara H, Miya TR, Singh N, Archer B, Qazi Y, Jackman K, Das SK, Olsen T, Chennamaneni SR, Stagg BC, Ahmed F, Emerson L, Zygmunt K, Whitaker R, Mamalis C, Huang W, Gao G, Srinivas SP, Krizaj D, Baffi J, Ambati J, Kompella UB, Ambati BK. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano. 2013 Apr 23;7(4):3264-75. doi: 10.1021/nn305958y. Epub 2013 Mar 20.</citation>
    <PMID>23464925</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Balamurali Ambati</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>corneal neovascularization</keyword>
  <keyword>Gamunex-C</keyword>
  <keyword>IVI-g</keyword>
  <keyword>anterior segment inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Corneal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

